JO3627B1 - إيميدازو بيرازينونات على هيئة مثبطات pde1 - Google Patents

إيميدازو بيرازينونات على هيئة مثبطات pde1

Info

Publication number
JO3627B1
JO3627B1 JOP/2016/0081A JOP20160081A JO3627B1 JO 3627 B1 JO3627 B1 JO 3627B1 JO P20160081 A JOP20160081 A JO P20160081A JO 3627 B1 JO3627 B1 JO 3627B1
Authority
JO
Jordan
Prior art keywords
imidazopyrazinones
pde1 inhibitors
pde1
inhibitors
medicament
Prior art date
Application number
JOP/2016/0081A
Other languages
English (en)
Inventor
Juhl Karsten
Kyhn Rasmussen Lars
Langgard Morten
Jessing Mikkel
Kehler Jan
Jorge Vieira Vital Paulo
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of JO3627B1 publication Critical patent/JO3627B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

يتعلق الاختراع الحالي بتوفير إيميدازو بيرازينونات على هيئة مثبطات PDE1 واستخدامها على هيئة دواء، بالتحديد لمعالجة اضطرابات التنكسية العصبية واضطرابات نفسية.
JOP/2016/0081A 2015-04-30 2016-04-26 إيميدازو بيرازينونات على هيئة مثبطات pde1 JO3627B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201500261 2015-04-30
DKPA201500666 2015-10-29
DKPA201600202 2016-04-04

Publications (1)

Publication Number Publication Date
JO3627B1 true JO3627B1 (ar) 2020-08-27

Family

ID=55910242

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0081A JO3627B1 (ar) 2015-04-30 2016-04-26 إيميدازو بيرازينونات على هيئة مثبطات pde1

Country Status (41)

Country Link
US (4) US20160318939A1 (ar)
EP (1) EP3288944B1 (ar)
JP (1) JP6663930B2 (ar)
KR (1) KR102605759B1 (ar)
CN (1) CN107531714B (ar)
AU (1) AU2016256573B2 (ar)
BR (1) BR112017023182B1 (ar)
CA (1) CA2983563A1 (ar)
CL (1) CL2017002719A1 (ar)
CO (1) CO2017010399A2 (ar)
CY (1) CY1121806T1 (ar)
DK (1) DK3288944T3 (ar)
DO (1) DOP2017000254A (ar)
EA (1) EA031946B1 (ar)
EC (1) ECSP17072228A (ar)
ES (1) ES2735422T3 (ar)
GE (1) GEP20207058B (ar)
GT (1) GT201700223A (ar)
HK (1) HK1252098B (ar)
HR (1) HRP20191180T1 (ar)
HU (1) HUE044244T2 (ar)
IL (1) IL255316B (ar)
JO (1) JO3627B1 (ar)
LT (1) LT3288944T (ar)
MA (1) MA41977B1 (ar)
ME (1) ME03414B (ar)
MX (1) MX2017013785A (ar)
MY (1) MY182382A (ar)
PE (1) PE20180121A1 (ar)
PH (1) PH12017501990B1 (ar)
PL (1) PL3288944T3 (ar)
PT (1) PT3288944T (ar)
RS (1) RS59051B1 (ar)
RU (1) RU2712219C2 (ar)
SG (1) SG11201708822PA (ar)
SI (1) SI3288944T1 (ar)
TN (1) TN2017000428A1 (ar)
TW (1) TWI695838B (ar)
UA (1) UA123050C2 (ar)
WO (1) WO2016174188A1 (ar)
ZA (1) ZA201706847B (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之***並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
MA46621A (fr) 2016-10-28 2021-06-02 H Lundbeck As Traitements combinés comprenant l'administration d'imidazopyrazinones
CN109803658A (zh) 2016-10-28 2019-05-24 H.隆德贝克有限公司 包含用于治疗精神疾病和/或认知障碍的咪唑并吡嗪酮的组合治疗
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN117447475A (zh) 2017-12-20 2024-01-26 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
WO2004099211A1 (de) 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
EA012873B1 (ru) * 2004-04-02 2009-12-30 Оси Фармасьютикалз, Инк. 6,6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ
US7872124B2 (en) * 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007025103A2 (en) * 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Organic compounds for treating reduced dopamine receptor signalling activity
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
EP2089034A4 (en) 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
MX2009011830A (es) 2007-05-11 2009-11-13 Pfizer Compuestos amino-heterociclicos.
AU2008329072A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
AP2011005672A0 (en) 2008-09-08 2011-04-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of CNS disorders.
EA201170772A1 (ru) * 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US8748386B2 (en) 2009-06-10 2014-06-10 New York University Immunological targeting of pathological Tau proteins
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
SI3042917T1 (en) 2010-08-12 2018-04-30 Eli Lilly And Company PROTITELES AGAINST N3PGL AMILOID BETA PEPTID AND THEIR APPLICATION
CN103313988B (zh) * 2010-09-20 2016-06-08 论坛医药有限公司 咪唑并三嗪酮化合物
WO2012040048A2 (en) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
JP2015531401A (ja) * 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノン骨格を有するｐｄｅ９ｉ
CN107082783B (zh) 2012-01-26 2019-03-22 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
JP2013166727A (ja) 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
IN2015DN00334A (ar) 2012-06-18 2015-06-12 Dart Neuroscience Cayman Ltd
US9598426B2 (en) 2013-03-15 2017-03-21 Intra-Cellular Therapies, Inc. Organic compounds
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
US20170066741A1 (en) 2014-02-19 2017-03-09 H. Lundbeck A/S 2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
JP2017527606A (ja) 2014-09-18 2017-09-21 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 三環系誘導体
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之***並吡酮
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
US20180044343A1 (en) 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
MX2018001699A (es) 2015-08-12 2018-05-07 H Lundbeck As 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1.
AR107456A1 (es) 2016-02-12 2018-05-02 Lilly Co Eli Inhibidor de pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
MA46621A (fr) 2016-10-28 2021-06-02 H Lundbeck As Traitements combinés comprenant l'administration d'imidazopyrazinones
CN109803658A (zh) 2016-10-28 2019-05-24 H.隆德贝克有限公司 包含用于治疗精神疾病和/或认知障碍的咪唑并吡嗪酮的组合治疗

Also Published As

Publication number Publication date
RU2712219C2 (ru) 2020-01-27
EA031946B1 (ru) 2019-03-29
PH12017501990A1 (en) 2018-03-26
ECSP17072228A (es) 2018-02-28
EP3288944B1 (en) 2019-06-12
ES2735422T3 (es) 2019-12-18
US20210238182A1 (en) 2021-08-05
SI3288944T1 (sl) 2019-08-30
US20160318939A1 (en) 2016-11-03
WO2016174188A1 (en) 2016-11-03
PE20180121A1 (es) 2018-01-18
HK1252098B (zh) 2020-02-07
IL255316B (en) 2021-10-31
SG11201708822PA (en) 2017-11-29
UA123050C2 (uk) 2021-02-10
ME03414B (me) 2020-01-20
RU2017137514A3 (ar) 2019-07-17
MA41977A (fr) 2018-07-23
DK3288944T3 (da) 2019-07-22
AU2016256573B2 (en) 2019-11-21
LT3288944T (lt) 2019-07-25
HRP20191180T1 (hr) 2019-10-04
BR112017023182A2 (ar) 2018-10-02
DOP2017000254A (es) 2018-01-15
JP2018514552A (ja) 2018-06-07
US10858362B2 (en) 2020-12-08
MA41977B1 (fr) 2019-08-30
PT3288944T (pt) 2019-07-19
KR20170140216A (ko) 2017-12-20
CA2983563A1 (en) 2016-11-03
GEP20207058B (en) 2020-01-27
JP6663930B2 (ja) 2020-03-13
US20190062335A1 (en) 2019-02-28
TW201700477A (zh) 2017-01-01
RU2017137514A (ru) 2019-05-31
CO2017010399A2 (es) 2018-01-05
PH12017501990B1 (en) 2018-03-26
CY1121806T1 (el) 2020-07-31
US20170291903A1 (en) 2017-10-12
EA201792157A1 (ru) 2018-03-30
ZA201706847B (en) 2019-01-30
RS59051B1 (sr) 2019-08-30
TWI695838B (zh) 2020-06-11
HK1252098A1 (zh) 2019-05-17
MX2017013785A (es) 2018-03-27
GT201700223A (es) 2018-12-19
CN107531714A (zh) 2018-01-02
CL2017002719A1 (es) 2018-04-20
CN107531714B (zh) 2019-07-19
TN2017000428A1 (en) 2019-04-12
KR102605759B1 (ko) 2023-11-23
US11472810B2 (en) 2022-10-18
HUE044244T2 (hu) 2019-10-28
BR112017023182B1 (pt) 2023-10-31
EP3288944A1 (en) 2018-03-07
MY182382A (en) 2021-01-22
PL3288944T3 (pl) 2019-11-29
IL255316A0 (en) 2017-12-31
AU2016256573A1 (en) 2017-12-14
US10011606B2 (en) 2018-07-03

Similar Documents

Publication Publication Date Title
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
GB2541571A (en) Pharmaceutical compositions
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2015013378A (es) Uso de sedoheptulosa para la prevencion y tratamiento de inflamacion.